About this release
This release is a weekly report on epidemiological information on seasonal respiratory infection activity in Scotland. Due to the COVID-19 pandemic, health care services are functioning differently now compared to previous flu seasons so the consultation rates are not directly comparable to historical data.
- The proportion of NHS24 calls for respiratory symptoms remained at Baseline activity level overall.
- Influenza incidence remained at Low activity level overall.
- There were 160 influenza cases: 128 type A (subtype unknown), 18 A(H1N1)pdm09, eight A(H3) and six type B. This compares to 146 laboratory-confirmed cases reported during week 41.
- Seasonal Coronavirus (non-SARS-CoV-2), HMPV, parainfluenza and Mycoplasma pneumoniae remained at Baseline activity level.
- Adenovirus, rhinovirus and RSV remained at Low activity level.
- The number of laboratory-confirmed RSV cases was 199. This compares with 218 laboratory-confirmed cases in week 41.
- Three NHS Boards were at Baseline, eight were at Low and three were at Moderate activity level.
- The under 1, 1-4 and 65-74 age groups remained at Low activity level. The 45-64 age group decreased from Moderate to Low activity level. The 15-44 and over 75 age groups remained at Moderate activity level. The 5-14 age group decreased from Extraordinary to Moderate activity level. The majority (61.8%) of RSV detections in week 42 were in those aged under 5 years and the majority (74.9%) of diagnoses across all age groups occurred in the hospital setting.
- The hospitalisation rate for influenza has been increasing since week 25 and was 1.4 per 100,000 in week 41, with the highest hospital admission rate for confirmed influenza noted in patients aged 75 years old and above (4.3 per 100,000). The current hospitalisation rate for influenza is lower than that for the five previous seasons prior to the COVID-19 pandemic.
- The hospitalisation rate for RSV was 2.2 per 100,000 in week 41, with the highest hospital admission rate for confirmed RSV noted in patients aged less than one year old (100.8 per 100,000). The hospitalisation rate for RSV peaked in week 38 and 39 in 2021 (4.5 per 100,000).
- Influenza vaccine data for the 2022/23 winter programme are now available on the PHS flu and COVID winter vaccination dashboard.
- These data indicate that at the end of week 42, an estimated total of 1,248,786 individuals have received their vaccine. This includes 1,037,577 eligible adults of whom 778,622 are aged 65 years and over. In addition, 94% of those receiving their COVID winter booster and eligible for flu vaccine have received both vaccines at the same appointment.
Surveillance of respiratory infection is a key public health activity as it is associated with significant morbidity and mortality during the winter months, particularly in those at risk of complications of flu e.g. the elderly, those with chronic health problems and pregnant women.
The spectrum of respiratory illnesses vary from asymptomatic illness to mild/moderate symptoms to severe complications including death. There is no single respiratory surveillance component that can describe the onset, severity and impact of influenza or the success of its control measures each season across a community.
This requires a number of complementary surveillance components which are either specific to respiratory infections or their control, or which are derived from data streams providing information of utility for other PHS specialities (corporate surveillance data). Together, the respiratory surveillance components provide a comprehensive and coherent picture on a timely basis throughout the flu season. Please see the influenza page on the HPS website (external website) for more details.
The next release of this publication will be 2 November 2022.
If you have an enquiry relating to this publication, please contact firstname.lastname@example.org.
If you have a media enquiry relating to this publication, please contact the Communications and Engagement team.
Requesting other formats and reporting issues
If you require publications or documents in other formats, please email email@example.com.
To report any issues with a publication, please email firstname.lastname@example.org.